Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MITO CERV 3 neoadjuvant pembrolizumab plus carboplatin and paclitaxel for locally advanced cervical cancer
2019-000318-12Phase 2Completed
- Sponsor
- Policlinico Gemelli
- Start
- Jun 2021
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab, carboplatin and paclitaxel in Cervical Cancer (CC), sponsored by Policlinico Gemelli. Primary endpoint: 2-year progression-free survival. Started Jun 2021; status: completed.
02
Drugs
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on 2019-000318-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-000318-12.